Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free public preview Track CING with free AI briefings, catalyst countdowns, and dilution alerts.

CING

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$25.9M Cash on Hand
14.8mo Cash Runway
21% Short Interest

🧪 Upcoming Trial Catalysts

📊 Drug Pipeline

DrugIndicationPhaseStatus
CTx-1301 - Dexmethylphenidate 18.75mg ADHD PHASE3 SUSPENDED
CTx-1301-Dexmethylphenidate 37.5 mg (ran ADHD PHASE3 COMPLETED
CTx-1301-Dexmethylphenidate 25mg (random ADHD PHASE3 COMPLETED
CTx-1301-Dexmethylphenidate 18.75mg (ran ADHD PHASE3 COMPLETED
CTx-1301-Dexmethylphenidate 12.5 mg (tit ADHD PHASE3 COMPLETED
CTx-1301 - Dexmethylphenidate 6.25mg ADHD PHASE3 SUSPENDED
CTx-1301 - Dexmethylphenidate 50mg ADHD PHASE3 COMPLETED
CTx-1301 - Dexmethylphenidate 37.5mg ADHD PHASE3 SUSPENDED
CTx-1301 - Dexmethylphenidate 31.25mg ADHD PHASE3 SUSPENDED
CTx-1301 - Dexmethylphenidate 25mg ADHD PHASE3 COMPLETED

💰 Cash Runway & Dilution Risk

CING holds $25.9M in cash and burns about $5.3M/quarter from operations, giving an estimated runway of 14.8 months. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for CING free →

📈 Recent Insider Activity (Form 4)

DateInsiderTypeValue
2026-06-08 Hargroves Thomas Jeffrey
Purchase $491,239
2026-06-08 Hargroves Thomas Jeffrey
Purchase $7,782
2026-06-08 Hargroves Thomas Jeffrey
Purchase $0
2026-05-08 Silva Raul R.
Purchase $0
2026-03-11 Brams Matthew
Purchase $0

Get the full CING picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for CING and 2 more tickers of your choice.

Create Free Account →
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.